Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome
unpredictable and potentially fatal acute pancreatitis. In addition to acute pancreatitis, FCS patients are at risk of
chronic complications due to permanent organ damage, including chronic pancreatitis and type 3c diabetes. There are currently no approved therapies for the treatment of FCS in the U.S. Fast Track designation is designed to expedite the FDA's review of innovative, new drugs that demonstrate the potential to address unmet medical need.